Meeting
2013 ASCO Annual Meeting
Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; R) on the pharmacokinetics (PK) of Cbz.
Authors
Alain C. Mita
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
Alain C. Mita , Albert C. Lockhart , James Lloyd Wade , John Charles Morris , Olivier Rixe , Jean-François Dedieu , Claudine Wack , Laurent Kassalow , John Sarantopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT00925743
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2560)
DOI
10.1200/jco.2013.31.15_suppl.2560
Abstract #
2560
Poster Bd #
4D
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors.
First Author: Albert C. Lockhart
Poster
2013 ASCO Annual Meeting
A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors.
First Author: Monica Arnedos
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez
Poster
2012 ASCO Annual Meeting
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
First Author: Serena Marchetti